J3031 Injection., fremanezumab-vfrm 1 milligrams
Also known as: fremanezumab, Ajovy, CGRP antagonist
Fremanezumab-vfrm (Ajovy) 1 milligram injection is a monoclonal antibody that blocks calcitonin gene-related peptide ligand, administered for chronic migraine prevention.
In Plain Language
migraine prevention injection; monthly migraine shot
Clinical Context
Indicated for chronic migraine prevention in patients with four or more migraine days per month. Administered monthly or quarterly depending on formulation. Reduces migraine frequency by targeting neuroinflammatory pathways.
RVU Information
CPT J3031 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3031?
CPT J3031 (Injection., fremanezumab-vfrm 1 milligrams) is a J Codes (Drugs) code. Fremanezumab-vfrm (Ajovy) 1 milligram injection is a monoclonal antibody that blocks calcitonin gene-related peptide ligand, administered for chronic migraine prevention.
How is J3031 administered?
CPT J3031 is administered by a healthcare provider, typically via injection or infusion. Indicated for chronic migraine prevention in patients with four or more migraine days per month. Administered monthly or quarterly depending on formulation. Reduces migraine frequency by targeting neuroinflammatory pathways. It is used by Neurology, Pain Management, Headache Specialists.
When is CPT J3031 used?
Indicated for chronic migraine prevention in patients with four or more migraine days per month. Administered monthly or quarterly depending on formulation. Reduces migraine frequency by targeting neuroinflammatory pathways.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.